The Effects of a Novel Mitochondrial Substrate Supplement on Exercise Performance and Cognitive Function
Launched by UNIVERSITY OF EXETER · Apr 16, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new dietary supplement designed to see if it can improve exercise performance and cognitive function, which is how well we think and remember. The trial will involve 40 healthy individuals, split into two age groups: young adults aged 18-30 and older adults aged 50-65. Participants will take the supplement for 16 days and will then complete tests to measure their exercise abilities on a stationary bike and their cognitive skills. After a break to ensure the supplement is out of their system, they will switch to a placebo, which looks and tastes the same but contains no active ingredients, and repeat the tests.
To be eligible for this study, participants need to be healthy, able to engage in intense exercise, and not overweight or obese. They should also not have any serious health conditions that could affect their ability to exercise safely. Throughout the trial, participants will make five visits to the lab for cognitive tests, exercise performance tests, and to provide blood samples. This study could help us understand if this new supplement truly has benefits for both physical and mental performance.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants will be deemed eligible to participate provided they are willing and able to follow the study instructions and
- • 1. are able to take part in intense exercise (as assessed via Physical Activity Readiness Questionnaire (PARQ))
- • 2. are able to consume a dietary supplement
- • 3. are not overweight/obese (assessed by BMI)
- • 4. do not have any cardiovascular, respiratory, metabolic or musculoskeletal disorders, or any other contraindication to the performance of maximal exercise.
- Exclusion Criteria:
- • 1. Aged 31-49 and aged 66+.
- • 2. underlying illness or injury (assessed via PARQ)
- • 3. overweight or obese individuals (BMI of \>30 kg.m-2).
- • 4. Cardiovascular, respiratory, metabolic or musculoskeletal disorders (assessed by screening form).
- • 5. Use of dietary supplements, tobacco smoking.
- • 6. Pregnant
About University Of Exeter
The University of Exeter is a leading research institution in the United Kingdom, renowned for its commitment to advancing knowledge and innovation across various disciplines, including health and medicine. As a clinical trial sponsor, the university leverages its extensive academic expertise and state-of-the-art facilities to conduct rigorous and ethically sound research. The University of Exeter aims to translate scientific findings into practical applications that improve patient outcomes and inform public health strategies, fostering collaboration between researchers, healthcare professionals, and community stakeholders to address critical health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Exeter, Devon, United Kingdom
Patients applied
Trial Officials
Andy M Jones, PhD, DSc
Principal Investigator
University of Exeter
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported